Editorial: Agency in denial - Stem cell board lacks money, not issues [California]
By Sacramento Bee,
Sacramento Bee
| 08. 13. 2005
People who suffer a serious medical setback often can't come to grips with it. Paralyzed stroke victims, for instance, sometimes insist they can raise their arms when they can't.
Doctors call this disorder "denial syndrome". California's $3 billion stem cell research institute appears to be afflicted by it.
Lawsuits filed by opponents of embryonic stem cell research have prevented the state from issuing bonds for the Institute for Regenerative Medicine, putting the whole program in limbo. These lawsuits are hugely dispiriting to Californians who support stem cell research, but they are a reality, and they could delay the institute's research grants by one or two years.
Institute leaders need to make the most of this lull by settling issues that will continue to dog the institute over the next decade. Instead, Institute Chairman Robert Klein II continues to toot his horn and cry "full steam ahead!" even as his ship remains tethered to the dock.
The latest exercise in institutional denial came Aug. 3 in San Francisco, where the institute held the first meeting of its grants review committee. The...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
